Cellectar Biosciences, Inc.
CLRB
$3.08
-$0.17-5.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.22% | -35.26% | 13.71% | 66.19% | 119.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.62% | -41.77% | -19.21% | 9.28% | 32.90% |
| Operating Income | 55.62% | 41.77% | 19.21% | -9.28% | -32.90% |
| Income Before Tax | 51.05% | 62.55% | 45.30% | 60.70% | -3.93% |
| Income Tax Expenses | -- | 210.00% | 210.00% | 210.00% | 210.00% |
| Earnings from Continuing Operations | 51.12% | 62.38% | 45.11% | 60.56% | -4.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.12% | 62.38% | 45.11% | 60.56% | -4.23% |
| EBIT | 55.62% | 41.77% | 19.21% | -9.28% | -32.90% |
| EBITDA | 55.78% | 41.89% | 19.28% | -9.28% | -32.80% |
| EPS Basic | 74.61% | 80.37% | 77.21% | 84.61% | 62.31% |
| Normalized Basic EPS | 74.58% | 80.50% | 77.29% | 84.66% | 62.40% |
| EPS Diluted | 77.65% | 82.20% | 77.35% | 79.82% | 57.19% |
| Normalized Diluted EPS | 74.47% | 80.44% | 77.43% | 84.80% | 62.55% |
| Average Basic Shares Outstanding | 113.37% | 93.34% | 91.87% | 143.65% | 199.55% |
| Average Diluted Shares Outstanding | 110.37% | 90.02% | 89.02% | 146.76% | 203.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |